ARA-290 is a research compound. It is not approved by the FDA or any regulatory body for human use. This article is for educational and informational purposes only. Nothing here constitutes medical advice. Consult a qualified physician before considering any peptide use.
ARA-290 is Investigational. Underwent Phase II clinical trials. Not FDA-approved. Regulations vary by country, and the legal landscape for peptides is evolving. This guide covers the current legal status and what researchers need to know.
Is ARA-290 Legal?
Investigational. Underwent Phase II clinical trials. Not FDA-approved.
The legal landscape for peptides like ARA-290 is nuanced and varies by jurisdiction. This guide covers the current regulatory status and what researchers need to know.
What Is the Legal Status of ARA-290 in the United States?
ARA-290 is generally available as a research chemical in the US. It is not FDA-approved for human use, which means it cannot be marketed, sold, or prescribed as a drug or supplement.
However, research chemicals can be legally purchased for laboratory, in vitro, or educational use. The key legal distinction is between personal research use and human consumption — the latter is not approved.
Is ARA-290 Legal Internationally?
Peptide regulations vary significantly by country. Some jurisdictions classify peptides as prescription-only compounds, while others allow research chemical sales similar to the US.
Australia: Most peptides require a prescription. UK: Generally available for research. Canada: Research chemical status. EU: Varies by country. Always check local regulations before purchasing.
Is ARA-290 Banned in Sports?
ARA-290 may be subject to anti-doping regulations depending on its class and mechanism. Athletes should check the current WADA prohibited list.
If you compete in any organized sport, assume all peptides are prohibited unless you have confirmed otherwise with your sport's governing body.
How Is the Legal Landscape Changing?
Peptide regulation is an evolving area. The FDA has increased scrutiny of compounding pharmacies and research chemical vendors in recent years. Some peptides that were freely available have faced new restrictions.
Staying informed about regulatory changes is important for researchers working with ARA-290 and similar compounds.
Bottom Line on ARA-290 Legality
Investigational. Underwent Phase II clinical trials. Not FDA-approved. Researchers should ensure compliance with their local laws and use ARA-290 only for legitimate research purposes.
Complete Guide
ARA-290 : Benefits, Dosage, Side Effects & Research
Related Reading
- ARA-290 Dosage Guide
- ARA-290 Benefits
- ARA-290 Side Effects
- ARA-290 Stacking Guide
- ARA-290 Cycle Guide
- ARA-290 Research
Calculate Your ARA-290 Dose
Use our free peptide dosing calculator to get exact reconstitution math and syringe units for ARA-290.
Open Calculator →Research-Grade Sourcing
If you're going to research ARA-290, source matters. These are the suppliers WolveStack has vetted for purity and third-party testing.
Frequently Asked Questions
What is ARA-290?
ARA-290 (Erythropoietin-derived tissue-protective peptide) is a Innate repair receptor agonist, anti-inflammatory peptide. Synthetic 11-amino acid peptide engineered from the tissue-protective domain of erythropoietin (EPO). It is researched for neuropathic pain relief, inflammation reduction, nerve fiber regeneration, improved autonomic function, metabolic control in diabetes.
What is the recommended ARA-290 dosage?
Common dosages: 2-4 mg daily administered once daily via subcutaneous injection. Cycle length: 28 days typical; 8-16 weeks for extended response. Half-life: approximately 24 hours. Use our peptide calculator for exact reconstitution math.
What are the side effects of ARA-290?
Safe profile in multiple clinical trials. Minimal reported adverse events. Occasional mild injection site reactions. No serious safety concerns identified across diabetes, sarcoidosis, and neuropathy patient populations.
Is ARA-290 safe?
ARA-290 has shown a preliminary safety profile in research. Investigational. Underwent Phase II clinical trials. Not FDA-approved. All research should follow appropriate safety protocols.